Nasus Pharma Ltd.

NSRX: 6-K · proxy statement

Nasus Pharma Ltd. held its Annual and Special General Meeting of Shareholders on October 8, 2026, with a quorum present. Shareholders approved all agenda items by the applicable required majority, except for Proposal No. 4 from the meeting notice and proxy statement furnished on Form 6-K on September 4, 2026. The failure of a single proposal is not explained in this filing and may warrant a review of the prior proxy statement for details. The report is incorporated by reference into the company's F-3 shelf (No. 333-298693) and S-8 registration statements.

SEC 6-K•18d ago

NSRX: 6-K · offering registration

Nasus Pharma entered into an at-the-market sales agreement with BTIG, LLC on September 18, 2026, giving the clinical-stage drug developer the ability to sell up to $8,500,000 of ordinary shares from time to time at prevailing market prices on NYSE American. Sales will be made under the company's Form F-3 shelf registration (File No. 333-298693) declared effective September 11, 2026 and a prospectus supplement dated the same day as the agreement. BTIG, acting as sales agent, receives a commission of up to 3.0% of gross proceeds plus expense reimbursements capped at $75,000 at signing and $15,000 per fiscal period thereafter, and the company is under no obligation to sell any shares. Proceeds are earmarked for ongoing clinical development of NS002 for anaphylaxis, initiation of clinical studies for other pipeline products, and working capital and general corporate purposes. No shares are being sold now, but the program creates a standing dilution overhang typical of clinical-stage biotechs funding trials through equity.

SEC 6-K•1mo ago

Nasus Pharma to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

Nasus Pharma will participate and present at the H.C. Wainwright 28th Annual Global Investment Conference, held September 14-16, 2026 at the Lotte New York Palace hotel in New York. CEO Brendan O'Grady and CFO Eyal Rubin will take one-on-one investor meetings throughout the conference, and the company's presentation will be available on demand from September 11. The release also reiterates that lead candidate NS002, an intranasal epinephrine treatment for Type I allergic reactions including anaphylaxis, is planned to enter a pivotal trial in Q4 2026 with topline data expected in Q1 2027.

•1mo ago

NSRX: 6-K · proxy statement

Nasus Pharma Ltd furnished a Form 6-K containing the notice, proxy statement, and proxy card for its Annual and Special General Meeting of Shareholders to be held October 8, 2026 in Tel Aviv. Shareholders of record at the close of business on September 14, 2026 are entitled to vote, and a quorum requires holders of at least 25% of outstanding ordinary shares. Proposals include re-appointing Brightman Almagor Zohar & Co. (Deloitte Israel) as independent auditor, re-appointing David Silberman and Dr. Sharon Shacham as Class I directors for three-year terms through the 2029 AGM, and approving new CEO Brendan P. O'Grady's package: a US$500,000 base salary, annual bonus up to 50% of base, a US$750,000 change-of-control or asset-sale transaction bonus, and options on 280,000 shares at stepped exercise prices of US$3.50, US$4.25 and US$5.00. Shareholders will also vote on a US$70,000 one-time bonus for former CEO Dan Teleman tied to his role in the roughly US$15 million PIPE that closed February 13, 2026, and on increasing ISO-eligible shares under the 2019 Incentive Option Plan U.S. Sub-Plan from 105,611 to 305,611. Proposals 3 and 4 require a special majority under Israeli law, and the board unanimously recommends FOR all five voting items. This is routine governance housekeeping for the micro-cap Israeli biotech, though the CEO's change-of-control bonus provision is the term most likely to draw investor attention.

SEC 6-K•1mo ago

Nasus Pharma Announces Transition of Chief Financial Officer

Nasus Pharma announced that Chief Financial Officer Eyal Rubin will be leaving the company on September 18, 2026, to pursue an opportunity outside the life sciences industry. Oren Elmaliach, the Company's Director of Finance, has been appointed Interim CFO effective immediately. Mr. Rubin will remain with Nasus through his departure date to assist with the transition. Mr. Elmaliach is a certified public accountant with more than 15 years of experience and has been with the company since its inception.

•2mo ago

Life Sciences Virtual Investor Forum Presentations Now Available for On-Demand Viewing

Aspire Biopharma Holdings was listed as a presenting company at the recent Life Sciences Virtual Investor Forum hosted by Virtual Investor Conferences. The company's presentation materials are now available for on-demand viewing and will remain accessible for 90 days. This announcement was issued by the conference organizer, OTC Markets Group, and does not contain new material information about Aspire Biopharma.

•4mo ago

Life Sciences Virtual Investor Forum Agenda Announced for June 24th & 25th

Aspire Biopharma Holdings (ASBP) is scheduled to present at the upcoming Life Sciences Virtual Investor Forum on June 25, 2026, at 2:00 PM ET. The event is hosted by Virtual Investor Conferences and features a roster of life sciences companies, allowing investors to view presentations and schedule one-on-one meetings with management teams. Registration is free and open to investors who wish to attend the live sessions or access recorded content.

•4mo ago

Nasus Pharma to Participate in the Zacks Life Sciences Investor Forum

Nasus Pharma management will present live at the Zacks Life Sciences Investor Forum held virtually on June 24-25, 2026. The interactive forum allows investors to submit questions to management in real time, with a webcast replay available following the event. The clinical-stage company is focused on intranasal powder products, including the needle-free epinephrine candidate NS002.

•4mo ago

RedChip's Biotech Virtual Investor Conference Replays Now Available

RedChip Companies announced that on-demand replays are now available for its Biotech Resurgence investor conference, which featured executives from across the healthcare sector. Calidi Biotherapeutics was one of the presenting companies included in the event lineup, alongside IN8bio, DiaMedica Therapeutics, and Nasus Pharma. This release serves as a promotional notice for the conference content and does not contain any new clinical or financial updates regarding Calidi.

•6mo ago